All News
Are we putting the CAR-T before the horse?
CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure.
Read ArticlePsoriatic Arthritis: Which biologic agent is the best first choice?
A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease.
Read Article
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Links:
Links:
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Abstract 1657: Can LLMs track medication history? GPT-4 outperformed most LLMs in identifying TNFi start/stop events and reasons for switch. 💊 Common reasons for TNFi switching: lack of effectiveness, adverse events, and insurance/cost barriers. @RheumNow #ACR25 https://t.co/5FUR9tBoyu


